Addison Disease in Adults: Diagnosis and Management
Ali J. Chakera, MBChB, MRCP, Bijay Vaidya, PhD, FRCP Department of Endocrinology, Royal Devon & Exeter Hospital, Exeter, UK. ABSTRACT Addison disease is a rare but potentially fatal disorder of the adrenal glands. Its manifestations are often confused with many common disorders, and a high index of suspicion is required for the diagnosis. Optimum steroid replacement and patient education are vital for good quality of life and to prevent acute adrenal crisis in this condition. 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 409-413 KEYWORDS: Addison disease; Adrenal; Glucocorticoid; Hypoadrenalism; Mineralocorticoid Addison disease, or primary adrenal insufciency, is a chronic disorder of the adrenal cortex resulting in inade- quate production of glucocorticoid and mineralocorticoid. 1 It is a relatively rare disease with a prevalence of about 140 per million and an annual incidence about 4 per million in Western populations. 2 Addison disease is a potentially le- thal condition if left untreated, yet its diagnosis is often missed or delayed. Furthermore, recent studies have shown that treated patients with Addison disease have a perception of reduced health-related quality of life 2 and remain at risk of premature death. 3 CAUSES The most common cause of Addison disease in developed countries is autoimmune adrenalitis (Table 1). This can occur in isolation or as a part of the autoimmune polyen- docrinopathy syndromes (type 1 and type 2). In autoimmune polyendocrinopathy syndrome type 1, Addison disease occurs in association with autoimmune hypoparathyroidism, chronic mucocutaneous candidiasis, and other autoimmune disor- ders, including type 1 diabetes, chronic active hepatitis, primary gonadal failure, and autoimmune thyroid disease. In autoimmune polyendocrinopathy syndrome type 2, Ad- dison disease occurs in association with type 1 diabetes or autoimmune thyroid disease. Other autoimmune disorders, such as primary gonadal failure, pernicious anemia, and vitiligo also might be present. Several infective agents can affect the adrenal gland, resulting in adrenal failure. Tuberculosis remains the most common cause of Addison disease worldwide. Adrenoleukodystrophy is an important cause of Addison disease in men. It is caused by accumulation of very long- chain fatty acids in the adrenal gland as well as in the central and peripheral nervous system. Adrenal failure may precede neurological manifestations in this disorder. PRESENTATION Addison disease presents insidiously with nonspecic symptoms that easily can be mistaken for other more prev- alent conditions (Table 2). For example, its common symp- toms, chronic fatigue, malaise, and anorexia may mimic a depressive illness. Likewise, unintentional weight loss, nau- sea, vomiting, and vague abdominal pain may be confused with symptoms of a gastrointestinal or eating disorder. Symptoms of postural hypotension (syncope, postural diz- ziness) and hypoglycemia are late manifestations of the disease. Pigmentation of skin and mucous membranes, when present, is a cardinal sign of Addison disease. Several biochemical abnormalities may provide a clue to the diagnosis of Addison disease (Table 2). In a patient with unexplained hyponatremia, adrenal insufciency must be excluded before making the diagnosis of syndrome of in- appropriate antidiuretic hormone secretion. Likewise, in a patient with unexplained hyperkalemia, Addison disease Funding: The work of Dr. Vaidya was partly supported by the Pen- insula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC) Funding. Conict of Interest: None. Authorship: Both authors had access to the data and a role in writing the manuscript. Requests for reprints should be addressed to Bijay Vaidya, PhD, De- partment of Endocrinology, Royal Devon & Exeter Hospital, Exeter EX2 5DW, UK. E-mail address: bijay.vaidya@pms.ac.uk 0002-9343/$ -see front matter 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.amjmed.2009.12.017 must be considered as a possibility before treating the pa- tient with insulin and dextrose infusion. Some patients with Addison disease show a raised serum thyrotropin level at presentation. The diagnosis of Addison disease must be considered in a hypothyroid patient whose symptoms worsen after starting thyroxine. Furthermore, unexplained recurrent hypoglycemic episodes in a patient with type 1 diabetes should also raise a suspicion of Addison disease. About half of patients with Addison disease present acutely with adrenal crises. 1 This is a life-threatening emer- gency characterized by severe dehydration and circulatory shock. Many patients also have nausea, vomiting, and ab- dominal pain, which may lead to a misdiagnosis of an acute abdomen. Acute adrenal crisis is usually precipitated by infection or other forms of severe physiological stress. INVESTIGATIONS Diagnosing Addison Disease A morning serum cortisol level higher than 500 nmol/L (18 g/dL) usually excludes Addison disease, while a level below 165 nmol/L (6 g/dL) is suggestive of adre- nal insufciency. 1 However, most patients will need a short synacthen test for conrmation or exclusion of Addison disease. This involves injecting 250 g of syn- acthen (tetracosactrin; synthetic analogue of adrenocor- ticotrophic hormone [ACTH]) intramuscularly or intra- venously. Blood samples for serum cortisol are taken at 0, 30, and 60 minutes. An increase in serum cortisol level 30 or 60 minutes after the synacthen injection to above 500 nmol/L (18 g/dL) is considered a normal response, 1 Table 1 Important Causes of Addison Disease Causes Key Associated Features Autoimmunity Autoimmune polyendocrinopathy syndrome type 1 Hypoparathyroidism, mucocutaneous candidiasis, other autoimmune disorders. Autosomal recessive. Mutations in the autoimmune regulator-1 (AIRE-1) gene. Autoimmune polyendocrinopathy syndrome type 2 Autoimmune thyroid disease, autoimmune diabetes, other autoimmune disorders. Isolated autoimmune Addison disease Infective Tuberculosis Signs of active tuberculosis often absent. Adrenal calcication. Fungal Systemic infection with histoplasmosis, cryptococcosis, coccidioidomycosis. Often associated with immunodeciency. Acquired immune deciency syndrome Often associated with cytomegalovirus adrenalitis. Genetic Adrenoleukodystrophy Neurological decit, dementia, testicular failure. Elevated plasma very long-chain fatty acids. X-linked recessive. Mutations in the ATP-binding cassette subfamily D member 1 (ABCD1) gene. Congenital adrenal hyperplasia Ambiguous external genitalia. Salt wasting or hypertension in some forms. Autosomal recessive. Several forms due to mutations in different genes, most common form caused by mutations in the cytochrome P-450c21 (CYP21) gene. Adrenal hypoplasia congenita Hypogonadotropic hypogonadism. X-linked recessive. Mutations in the dosage-sensitive sex-reversal adrenal hypoplasia critical region on the x-chromosome protein 1 (DAX-1) gene. Familial glucocorticoid deciency Intact mineralocorticoid function. Autosomal recessive. Type 1 (tall stature; mutations in the melanocortin 2 receptor [MC2R] gene) and type 2 (normal stature; mutations in the melanocortin 2 receptor accessory protein [MRAP] gene). IMAGe syndrome Intra-uterine growth retardation, metaphyseal dysplasia, genital abnormalities. Genetic defect unknown. Allgrove syndrome (Triple A syndrome) Achalasia, alacrimia, mental retardation, deafness. Autosomal recessive. Mutations in the achalasia, adrenocortical insufciency, alacrimia syndrome (AAAS) gene. Kearns-Sayre syndrome (Mitochondrial Addison disease) Ophthalmoplegia, retinal degeneration, muscle weakness, cardiomyopathy, lactic acidosis, sensory deafness. Deletions in mitochondrial DNA. Miscellaneous Inltration Malignant: metastasis or lymphoma. Nonmalignant: amyloidosis, hemochromatosis or sarcoidosis. Hemorrhage Associated with meningococcal septicemia (Waterhouse- Fredrickson syndrome) or anticoagulation. Infarction Associated with antiphospholipid syndrome. Iatrogenic Bilateral adrenalectomy or drugs (ketoconazole, etomidate, aminoglutethimide, mitotane). 410 The American Journal of Medicine, Vol 123, No 5, May 2010 although the threshold cortisol level may vary according to local laboratory reference ranges. If the cortisol re- sponse to synacthen is inadequate, plasma ACTH level should be measured. A raised plasma ACTH level con- rms the diagnosis of Addison disease, whereas patients with secondary adrenal insufciency due to pituitary or hypothalamic disorders have a low or inappropriately normal plasma ACTH level. Plasma renin activity is elevated in Addison disease and is sometimes a useful investigation to distinguish between Addison disease and secondary adrenal insufciency. Investigating the Cause of Addison Disease Once a diagnosis of Addison disease is conrmed, further investigations are needed to elucidate the underlying cause (Figure). There may be clues in the history and examination. For example, a presence of another autoim- mune condition (eg, vitiligo) will point to autoimmune Figure Algorithm to determine the cause of Addison disease in adults. ACTH adrenocorticotrophic hormone; APS1 autoimmune polyendocrinopathy syndrome type 1; APS2 autoimmune polyendocrinopathy syndrome type 2; PTH parathyroid hor- mone; VLCFA very long-chain fatty acid. Table 2 Symptoms, Signs and Investigations that Point to Addison Disease Symptoms Signs Laboratory results Fatigue Malaise Loss of appetite Nausea and vomiting Abdominal pain Weight loss Postural dizziness Funny turns may be due to postural hypotension or hypoglycemia Myalgia Joint pain Salt craving Loss of libido (particularly in women) Hyperpigmentation of skin and mucous membranes Low blood pressure Postural hypotension Hyponatremia Hyperkalemia Hypoglycaemia Raised urea Metabolic acidosis Hypercalcemia Raised thyroid-stimulating hormone Normocytic anemia 411 Chakera and Vaidya Addison Disease Addison disease. Likewise, neurological manifestations in a young man should raise a suspicion of adrenole- ukodystrophy. The presence of adrenal antibodies indicates autoim- mune Addison disease. Ideally, both adrenal cortex antibod- ies and 21-hydroxylase antibodies should be measured. 4 21-hydroxylase antibodies are more sensitive than adrenal cortex antibodies in the diagnosis of autoimmune Addison disease. In patients with autoimmune Addison disease, it is important to screen for other features of autoimmune poly- endocrinopathy syndromes. In men with negative adrenal antibodies, plasma very long-chain fatty acids should be checked to exclude adrenoleukodystrophy. If the cause still remains unclear, a computed tomographic scan of the adre- nal glands should be carried out, which may show evidence of metastasis, inltration, hemorrhage, infarction, or infec- tion (for example, adrenal calcication in longstanding tuberculosis). MANAGEMENT Routine Management of Addison Disease Routine treatment of Addison disease involves replacement of the glucocorticoid and mineralocorticoid hormones. Some forms of Addison disease also will require specic treatment for the underlying cause, for example, antituber- culous drugs in Addison disease due to tuberculosis. Glucocorticoid Replacement. Hydrocortisone is most commonly used for glucocorticoid replacement, although other glucocorticoids, including cortisone, prednisolone, and dexamethasone are occasionally used. Long-acting glu- cocorticoids, dexamethasone, and prednisolone have the advantage of a once-daily dosing schedule but have the drawback of losing the diurnal pattern, resulting in excess glucocorticoid levels overnight. In Addison disease, standard replacement dose of hydro- cortisone is 15-25 mg a day, given in 2 or 3 divided doses. 1 A typical starting regime would consist of hydrocortisone 10 mg on waking, 5 mg at around noon, and 5 mg early evening. There are no satisfactory biochemical tests to as- sess the adequacy of glucocorticoid replacement. In prac- tice, the dose of hydrocortisone is maintained on the basis of clinical assessment, taking an account of patients well- being, and presence of any signs of over-replacement (eg, hypertension, weight gain, thin skin, easy bruising, and glucose intolerance) or under-replacement (eg, weight loss and pigmentation). During intercurrent illnesses, perioperative periods, and other forms of stress, patients should increase the dose of hydrocortisone to mimic the normal physiological response (Table 3). Some drugs (eg, rifampicin, phenobarbitone, and phenytoin) increase hepatic metabolism of glucocorticoids, and patients starting on such drugs may need to increase the dose of hydrocortisone. Mineralocorticoid Replacement. Fludrocortisone is the only available agent for mineralocorticoid replacement. The usual starting dose is 100 g a day. The dose is adjusted (usually 50-200 g a day) according to clinical response. Hypertension and presence of ankle edema suggest over- Table 3 Recommendations for an Increased Dose Hydrocortisone in Patients with Addison Disease in Different Conditions Conditions Increment in Hydrocortisone Dose Intercurrent illness Minor febrile illness (eg, common cold, viral chest infection) Double the dose. Taper down to the maintenance dose over 2-3 days after the illness. Persistent vomiting or diarrhea, or both (eg, gastroenteritis) Admission to hospital for intravenous hydrocortisone. Serious medical illness (eg, severe sepsis, myocardial infarction, pancreatitis) or major trauma Intravenous injections 50 mg every 8 h or continuous intravenous infusion 150 mg/24 h.* Surgery Minor surgery or invasive diagnostic procedure (eg, dental extraction, herniorrhaphy, gastroscopy, colonoscopy) Double the dose on the day. Major surgery (eg, intra-abdominal surgery, cardiothoracic surgery) Intravenous injections 50 mg every 8 h or continuous intravenous infusion 150 mg/24 h.* Following uncomplicated procedure, taper down to the maintenance dose over 2-3 days. Other Pregnancy Dose increment usually not necessary, but may need to give parenterally if unable to take oral medication because of nausea. During labor, double the dose. If unable to take orally, give a dose of 50 mg parenterally during the second stage. Physical exercise Dose increment not necessary for gentle exercise. Increase the dose by 5 mg before strenuous exercise. Psychologically stressful situation (eg, examination, interview) Dose increment not necessary. *No need to replace mineralocorticoid at these doses of hydrocortisone as high dose hydrocortisone has mineralocorticoid activity. 412 The American Journal of Medicine, Vol 123, No 5, May 2010 replacement, while salt craving, postural hypotension, and hyperkalemia are signs of under-replacement. An assess- ment of plasma renin activity also is helpful in optimizing the dose of udrocortisone, as suppressed and elevated plasma renin activity indicate over-replacement and under- replacement, respectively. Patient Education. Patient education is critical for the successful management of Addison disease. Information on management of steroid replacement during sickness can prevent acute adrenal crisis. Patients should carry a steroid card and a medic alert bracelet with details of the diagnosis. They and their family members should be taught to give intramuscular hydrocortisone injections during emergencies. Follow-up. Patients with Addison disease should be re- viewed annually to assess well-being, monitor whether the glucocorticoid and mineralocorticoid replacement is ade- quate, and reinforce patient education. In patients with au- toimmune Addison disease, you also should screen annually for associated autoimmune disorders with full blood count (pernicious anemia), fasting glucose (diabetes mellitus), and serum thyrotropin (thyroid dysfunction), and check the reg- ularity of menstrual cycle in women (premature ovarian failure). Management of an Adrenal Crisis An adrenal crisis is a life-threatening medical emergency that requires urgent hospital admission for treatment with intravenous hydrocortisone and crystalloid. Patients may need several liters of normal saline to maintain their blood pressure. The recommended initial dose of hydrocortisone is 100 mg, with subsequent doses of 100-200 mg over 24 hours divided into 3 or 4 doses. 1 The precipitating cause (for example, an infection) should be sought and treated. If acute adrenal crisis is suspected in an undiagnosed patient, the treatment should not be delayed to carry out diagnostic tests. Management Controversy: Dehydroepiandrosterone Replacement Dehydroepiandrosterone (DHEA) and dehydroepiandros- terone sulphate are androgens secreted by the adrenal cortex and are decreased in Addison disease. A meta-analysis of randomized controlled trials of DHEA treatment in women with Addison disease has shown evidence of a nominal benecial effect on health-related quality of life. 5 More long-term efcacy and safety data are needed before DHEA replacement can be advocated in routine clinical practice. FUTURE DEVELOPMENT Current regimes of glucocorticoid replacement in Addison disease are a poor surrogate for the homeostasis of endog- enous cortisol production. Endogenous cortisol secretion starts at around 3 AM, peaking in the morning after waking, and gradually wanes to nothing by midnight. A promising advance in the management of Addison disease is develop- ment of a modied-release hydrocortisone tablet that can mimic the circadian rhythm of endogenous cortisol produc- tion, 6 which might improve quality of life and other out- comes in patients with this condition. References 1. Arlt W, Allolio B. Adrenal insufciency. Lancet. 2003;361:1881- 1893. 2. Erichsen MM, Lovas K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufciency: ob- servations from a Norwegian Registry. J Clin Endocrinol Metab. 2009; 94:4882-4890. 3. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addisons disease: a population- based study. J Clin Endocrinol Metab. 2006;91:4849-4853. 4. Falorni A, Laureti S, De Bellis A, et al. Italian addison network study: update of diagnostic criteria for the etiological classication of primary adrenal insufciency. J Clin Endocrinol Metab. 2004;89: 1598-1604. 5. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treat- ment effects on quality of life in women with adrenal insufciency. J Clin Endocrinol Metab. 2009;94:3676-3681. 6. Debono M, Ghobadi C, Rostami-Hodjegan A, et al. Modied-release hydrocortisone to provide circadian cortisol proles. J Clin Endocrinol Metab. 2009;94:1548-1554. 413 Chakera and Vaidya Addison Disease